Palvella Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2025	FY 2024	FY 2023	FY 2023
Period Ending	Dec '25 Dec 31, 2025	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jun '23 Jun 30, 2023
Net Income	-41.72	-41.72	-17.43	18.69	-24.54
Stock-Based Compensation	6.4	6.4	0.83	0.6	3.35
Other Adjustments	6.49	6.43	5.96	-29.85	-
Change in Receivables	2.49	0.39	-1.98	-	-
Changes in Accounts Payable	1.26	1.26	2.24	-2.25	-
Changes in Accrued Expenses	-1.3	-1.3	1.05	-1.18	-
Changes in Other Operating Activities	1.36	1.36	-1.5	0.27	-
Operating Cash Flow	-25.01	-25.01	-10.84	-13.7	-53.82
Long-Term Debt Issued	-	-	18.43	-	-
Net Long-Term Debt Issued (Repaid)	-	-	18.43	-	-
Issuance of Common Stock	0.76	0.76	-	-	-
Net Common Stock Issued (Repurchased)	0.76	0.76	-	-	-
Other Financing Activities	-1.42	-1.27	68.66	5	-
Financing Cash Flow	-0.66	-0.66	87.09	5	19.8
Effect of Exchange Rate Changes on Cash and Cash Equivalents	0.05	0.05	0	-	0
Net Cash Flow	-25.62	-25.62	76.25	-8.7	-21.24
Free Cash Flow	-25.01	-25.01	-10.84	-13.7	-53.82
Free Cash Flow Per Share	-2.22	-2.26	-4.87	-7.64	-49.45
Levered Free Cash Flow	-40.39	-40.39	2.78	14.77	-24.54
Unlevered Free Cash Flow	-37.28	-37.28	-12.31	-15.02	-58.65

Updated Mar 31, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q